KRAUS JÖRG
Department of Laboratory Medicine
Institute of Neurointervention
Publications
|
Researcher Profile
147 Publications
2023
Journal Articles
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria
Guger, M; Enzinger, C; Leutmezer, F; Di Pauli, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T; Austrian MS Treatment Registry AMSTR
J NEUROL. 2023;
Full papers/articles (Journal)
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
Monschein, T; Dekany, S; Zrzavy, T; Ponleitner, M; Altmann, P; Bsteh, G; Kornek, B; Rommer, P; Enzinger, C; Di Pauli, F; Kraus, J; Berger, T; Leutmezer, F; Guger, M
J NEUROL. 2023;
Full papers/articles (Journal)
2022
Journal Articles
Laboratory biomarkers of Multiple Sclerosis (MS)
Arneth, B; Kraus, J
CLIN BIOCHEM. 2022; 99: 1-8.
Reviews
The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis
Arneth, B; Kraus, J
MEDICINA-LITHUANIA. 2022; 58(11): 1512
Reviews
Experimental laboratory biomarkers in multiple sclerosis.
Arneth, B; Kraus, J;
Wien Med Wochenschr. 2022; 172(15-16): 346-358.
Reviews
Conference papers, proceedings, abstracts
Horizontal versus vertical switch of treatment in patients with relapsing-remitting multiple sclerosis in Austria
Guger, M; Enzinger, C; Leutmezer, F; Di Pauli, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
MULT SCLER J. 2022; 28(3_SUPPL): 670-671.
Abstracts (Journal)
2021
Journal Articles
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger, M; Enzinger, C; Leutmezer, F; Di Pauli, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
J Neurol. 2021; 268(11):4303-4310
Full papers/articles (Journal)
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
Moser, T; OSullivan, C; Puttinger, C; Feige, J; Pilz, G; Haschke-Becher, E; Cadamuro, J; Oberkofler, H; Hitzl, W; Harrer, A; Kraus, J; Trinka, E; Wipfler, P;
Biomedicines. 2021; 9(11):
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Advanced Radiation Protection in PCI and Diagnostic Procedures With a Ceiling-Suspended Radiation Protection System-Data From the OSCAR Registry
Brandt, M; Prinz, E; Schernthaner, C; Kraus, J; Wintersteller, W; Hammerer, M; Strohmer, B; Lichtenauer, M; Motloch, L; Hoppe, U; Nairz, O
J AM COLL CARDIOL. 2021; 78(19): B63-B64.
Abstracts (Journal)
Improved protection for operator and assistant from occupational scatter radiation in interventional cardiologic procedures with a suspended radiation protection system-a per-procedure live-dosimetry analysis
Brandt, MC; Prinz, E; Wintersteller, W; Schernthaner, C; Hammerer, M; Kraus, J; Danmayr, F; Strohmer, B; Pretsch, I; Lichtenauer, M; Motloch, LJ; Hoppe, UC; Nairz, O
WIEN KLIN WOCHENSCHR. 2021; 133(SUPPL 3): S119-S119.
Abstracts (Journal)
Effective reduction of scatter radiation for operator and assistant during coronary procedures with a suspended radiation protection system in a per-procedure live-dosimetry analysis
Brandt, MC; Prinz, E; Wintersteller, W; Schernthaner, C; Hammerer, M; Kraus, J; Danmayr, F; Strohmer, B; Pretsch, I; Lichtenauer, M; Motloch, LJ; Hoppe, UC; Nairz, O
EUR HEART J. 2021; 42: 2098-2098.
Abstracts (Journal)
Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry
Guger, M; Enzinger, C; Leutmezer, F; Di Pauli, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
MULT SCLER J. 2021; 27(2_SUPPL): 629-630.
Abstracts (Journal)
2020
Journal Articles
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
J NEUROL. 2020; 267(7): 2090-2100.
Full papers/articles (Journal)
Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.
Pilz, G; Sakic, I; Wipfler, P; Kraus, J; Haschke-Becher, E; Hitzl, W; Trinka, E; Harrer, A;
Fluids Barriers CNS. 2020; 17(1): 7
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Oral therapies for treatment of relapsing-remitting multiple sclerosis in austria
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
MULT SCLER J. 2020; 26(3_SUPPL): 179-179.
Abstracts (Journal)
2019
Journal Articles
Do elevated autoantibodies in patients with multiple sclerosis matter?
Dal-Bianco, A; Wenhoda, F; Rommer, PS; Weber, M; Altmann, P; Kraus, J; Leutmezer, F; Salhofer-Polanyi, S;
Acta Neurol Scand. 2019; 139(3):238-246
Full papers/articles (Journal)
Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
J NEUROL. 2019; 266(11): 2672-2677.
Full papers/articles (Journal)
Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry (vol 266, pg 2672, 2019)
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
J NEUROL. 2019; 266(11): 2678-2678.
Corrections
Real-life use of oral disease-modifying treatments in Austria.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
ACTA NEUROL SCAND. 2019; 140(1): 32-39.
Full papers/articles (Journal)
Month-of-birth-effect in multiple sclerosis in Austria.
Walleczek, NK; Frommlet, F; Bsteh, G; Eggers, C; Rauschka, H; Koppi, S; Assar, H; Ehling, R; Birkl, C; Salhofer-Polanyi, S; Baumgartner, A; Blechinger, S; Buchinger, D; Sellner, J; Kraus, J; Moser, H; Mayr, M; Guger, M; Rathmaier, S; Raber, B; Liendl, H; Hiller, MS; Parigger, S; Morgenstern, G; Kempf, I; Spiss, HK; Meister, B; Heine, M; Cisar, A; Bachler, H; Khalil, M; Fuchs, S; Enzinger, C; Fazekas, F; Leutmezer, F; Berger, T; Kristoferitsch, W; Aboulenein-Djamshidian, F;
Mult Scler. 2019; 25(14): 1870-1877.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Switching natalizumab to fingolimod - real life data from Austria
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T
MULT SCLER J. Paracelsus Med Univ, Dept Lab Med, Salzburg, Austria. 2019; 25: 307-308.-35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS; SEP 11-13, 2019; Stockholm, SWEDEN.
Abstracts (Journal)
2018
Journal Articles
Late age onset of amyotrophic lateral sclerosis is often not considered in elderly people.
Broussalis, E; Grinzinger, S; Kunz, AB; Killer-Oberpfalzer, M; Haschke-Becher, E; Hartung, HP; Kraus, J;
Acta Neurol Scand. 2018; 137(3):329-334
Full papers/articles (Journal)
Real-life clinical use of natalizumab and fingolimod in Austria.
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Kalcher, S; Kvas, E; Berger, T;
Acta Neurol Scand. 2018; 137(2):181-187
Full papers/articles (Journal)
Geriatric Basics for the Neurohospitalist.
Heckmann, JG; Kraus, J; Lang, CJG;
Neurohospitalist. 2018; 8(2): 92-101.
Reviews
2017
Journal Articles
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Full papers/articles (Journal)
Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome.
Pilz, G; Wipfler, P; Schwarte, O; Golaszewski, S; McCoy, M; Haschke-Becher, E; Hartung, HP; Kraus, J;
J Neurol. 2017; 264(4): 799-801.
Letters
2015
Journal Articles
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Full papers/articles (Journal)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Full papers/articles (Journal)
Selecting a prospective test for early detection of diabetic polyneuropathy.
Ruhdorfer, AS; Azaryan, M; Kraus, J; Grinzinger, S; Hitzl, W; Ebmer, J; Dellon, AL; Hölzl, B;
Microsurgery. 2015; 35(7): 512-517.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Update - real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian multiple sclerosis treatment registry
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Berger, T
MULT SCLER J. 2015; 21: 281-281.
Abstracts (Journal)
2014
Journal Articles
TaqManR proximity ligation technology for the detection of heterodimeric adhesion receptors on lymphocytes.
Gehwolf, R; Band, E; Trost, A; Iglseder, B; Trinka, E; Haschke-Becher, E; Kraus, J; Harrer, A;
J Immunol Methods. 2014; 404:81-86
Full papers/articles (Journal)
High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.
Hegen, H; Guger, M; Harrer, A; Hoelzl, M; Kraus, J; Skrobal, A; Schautzer, F; Schmidegg, S; Schocke, M; Deisenhammer, F;
Mult Scler Relat Disord. 2014; 3(2):220-226
Full papers/articles (Journal)
Usability and Potential of Geostatistics for Spatial Discrimination of Multiple Sclerosis Lesion Patterns
Marschallinger, R; Golaszewski, SM; Kunz, AB; Kronbichler, M; Ladurner, G; Hofmann, P; Trinka, E; McCoy, M; Kraus, J
J NEUROIMAGING. 2014; 24(3): 278-286.
Full papers/articles (Journal)
A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Full papers/articles (Journal)
FADD is upregulated in relapsing remitting multiple sclerosis.
Reuss, R; Mistarz, M; Mirau, A; Kraus, J; Bodeker, RH; Oschmann, P
NEUROIMMUNOMODULAT. 2014; 21(5): 221-225.
Full papers/articles (Journal)
What to expect after natalizumab cessation in a real-life setting.
Salhofer-Polanyi, S; Baumgartner, A; Kraus, J; Maida, E; Schmied, M; Leutmezer, F
Acta Neurol Scand. 2014; 130(2):97-102
Full papers/articles (Journal)
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Ward-Abel, N; Köhler, W; Matthews, V; Uccelli, MM; Mouzawak, C; Ross, AP; Pyciaková, L; Winslow, A; Kraus, J;
Mult Scler. 2014; 20(4):403-405
Full papers/articles (Journal)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry
Guger, M; Enzinger, C; Leutmezer, F; Kraus, J; Berger, T
MULT SCLER J. 2014; 20: 198-198.
Abstracts (Journal)
Natalizumab and fingolimod differentially impact the alpha-4/beta-1 and alpha-L/beta-2 expression-related subset diversity of T-cells
Harrer, A; Oppermann, K; Wanek, J; Pilz, G; Wipfler, P; Sellner, J; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2014; 20: 333-333.
Abstracts (Journal)
Importance of CSF analysis in the era of McDonald 2010 criteria: a retrospective multicenter study in patients with a clinically isolated syndrome
Tumani, H; Trebst, C; Spreer, A; Borisow, N; Harrer, A; Brecht, I; Buttmann, M; Balint, B; Stich, O; Schlegel, S; Winkelmann, A; Roesler, R; Lauda, F; Huss, A; Yildiz, O; Voss, E; Muche, R; Rauer, S; Bergh, FT; Paul, F; Wildemann, B; Kraus, J; Ruprecht, K; Stangel, M; Otto, M; Zettl, UK
MULT SCLER J. 2014; 20: 155-156.
Abstracts (Journal)
2013
Journal Articles
Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People
Aboul-Enein, F; Seifert-Held, T; Mader, S; Kuenz, B; Lutterotti, A; Rauschka, H; Rommer, P; Leutmezer, F; Vass, K; Flamm-Horak, A; Stepansky, R; Lang, W; Fertl, E; Schlager, T; Heller, T; Eggers, C; Safoschnik, G; Fuchs, S; Kraus, J; Assar, H; Guggenberger, S; Reisz, M; Schnabl, P; Komposch, M; Simschitz, P; Skrobal, A; Moser, A; Jeschow, M; Stadlbauer, D; Freimuueller, M; Guger, M; Schmidegg, S; Franta, C; Weiser, V; Koppi, S; Niederkorn-Duft, M; Raber, B; Schmeissner, I; Jecel, J; Tinchon, A; Storch, MK; Reindl, M; Berger, T; Kristoferitsch, W
PLOS ONE. 2013; 8(11): e79649
Full papers/articles (Journal)
Treatment strategies for vasculitis that affects the nervous system.
Broussalis, E; Trinka, E; Kraus, J; McCoy, M; Killer, M;
Drug Discov Today. 2013; 18(17-18): 818-835.
Full papers/articles (Journal)
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Fazekas, F; Bajenaru, O; Berger, T; Fabjan, TH; Ledinek, AH; Jakab, G; Komoly, S; Kobys, T; Kraus, J; Kurča, E; Kyriakides, T; Lisý, L; Milanov, I; Nehrych, T; Moskovko, S; Panayiotou, P; Jazbec, SŠ; Sokolova, L; Taláb, R; Traykov, L; Turčáni, P; Vass, K; Vella, N; Voloshyná, N; Havrdová, E;
Front Neurol. 2013; 4: 10
Full papers/articles (Journal)
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Harrer, A; Tumani, H; Niendorf, S; Lauda, F; Geis, C; Weishaupt, A; Kleinschnitz, C; Rauer, S; Kuhle, J; Stangel, M; Weber, F; Uhr, M; Linnebank, M; Wildemann, B; Jarius, S; Guger, M; Ayzenberg, I; Chan, A; Zettl, U; Wiendl, H; Pilz, G; Hitzl, W; Weber, JR; Kraus, J;
Mult Scler. 2013; 19(9):1209-1212
Full papers/articles (Journal)
Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?
Nagy, K; Skagervik, I; Tumani, H; Petzold, A; Wick, M; Kühn, HJ; Uhr, M; Regeniter, A; Brettschneider, J; Otto, M; Kraus, J; Deisenhammer, F; Lautner, R; Blennow, K; Shaw, L; Zetterberg, H; Mattsson, N;
CLIN CHEM LAB MED. 2013; 51(11): 2073-2086.
Full papers/articles (Journal)
Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J;
Neurology. 2013; 81(19): 1654-1658.
Full papers/articles (Journal)
TRAF2 is upregulated in relapsing-remitting multiple sclerosis.
Reuß, R; Mirau, A; Mistarz, M; Kraus, J; Bödeker, RH; Oschmann, P;
Neuroimmunomodulation. 2013; 20(3):177-183
Full papers/articles (Journal)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Full papers/articles (Journal)
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.
Wipfler, P; Heikkinen, A; Harrer, A; Pilz, G; Kunz, A; Golaszewski, SM; Reuss, R; Oschmann, P; Kraus, J;
J Neurol. 2013; 260(1):221-227
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Shift in the CD4+/CD8+ratio of cerebrospinal fluid T cells independent from free or cell-bound natalizumab
Harrer, A; Oppermann, K; Pizl, G; Wipfler, P; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 451-452.
Abstracts (Journal)
Flow-cytometry and the detection of natalizumab-neutralizing antibodies in multiple sclerosis
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Holl, B; Deisenhammer, F; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 500-501.
Abstracts (Journal)
2012
Journal Articles
Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.
Broussalis, E; Hutterer, M; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Haschke-Becher, E; Golaszewski, S; Schönauer, U; Weis, S; Killer-Oberpfalzer, M; Mc Coy, M; Trinka, E; Kraus, J;
Acta Neurol Scand. 2012; 126(3):e11-e16
Case Reports
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention.
Broussalis, E; Killer, M; McCoy, M; Harrer, A; Trinka, E; Kraus, J;
Drug Discov Today. 2012; 17(7-8):296-309
Reviews
Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies.
Broussalis, E; Trinka, E; Killer, M; Harrer, A; McCoy, M; Kraus, J;
Drug Discov Today. 2012; 17(13-14):671-684
Reviews
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Fazekas, F; Berger, T; Fabjan, TH; Ledinek, AH; Jakab, G; Komoly, S; Kraus, J; Kurča, E; Kyriakides, T; Lisý, L; Milanov, I; Panayiotou, P; Jazbec, SS; Taláb, R; Traykov, L; Turčáni, P; Vass, K; Vella, N; Havrdová, E;
Wien Med Wochenschr. 2012; 162(15-16): 354-366.
Reviews
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Full papers/articles (Journal)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Full papers/articles (Journal)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Reviews
Biomarkers of Inflammation and Endothelial Dysfunction in Stroke with and without Sleep Apnea
Kunz, AB; Kraus, J; Young, P; Reuss, R; Wipfler, P; Oschmann, P; Blaes, F; Dziewas, R
CEREBROVASC DIS. 2012; 33(5): 453-460.
Full papers/articles (Journal)
Serum from interferon-beta-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro
Muller, M; Frese, A; Nassenstein, I; Hoppen, M; Marziniak, M; Ringelstein, EB; Kim, KS; Schabitz, WR; Kraus, J
MULT SCLER J. 2012; 18(2): 236-239.
Full papers/articles (Journal)
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Full papers/articles (Journal)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Natalizumab Treatment Effects Sustained Decrease in Serum Levels of Fibronectin and Soluble Adhesion Molecules sVCAM-1 and sICAM-3
Kraus, J; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Journal)
Serum Levels of Soluble Adhesion Molecules Remain Stable during Short- and Long-Term Interferon-beta-1b Treatment
Kraus, J; Zaunrieth, R; Obregon-Castrillo, E; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Golaszewski, S; Hitzl, W; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Journal)
2011
Journal Articles
Cerebral localized marginal zone lymphoma presenting as hypothalamic-pituitary region disorder.
Broussalis, E; Kraus, J; Kunz, AB; Luthringshausen, G; McCoy, M; Muss, W; Hutarew, G; Ladurner, G; Trinka, E; Killer-Oberpfalzer, M;
Case Rep Neurol. 2011; 3(2):129-135
Full papers/articles (Journal)
Isolated facial palsy and ophthalmoplegia--first symptoms of a cerebral granulomatous vasculitis with giant cells--a diagnostic challenge.
Broussalis, E; Luthringshausen, G; Kunz, AB; McCoy, M; Weiss, S; Killer-Oberpfalzer, M; Trinka, E; Kraus, J;
Clin Neurol Neurosurg. 2011; 113(8): 686-688.
Case Reports
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Full papers/articles (Journal)
Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy.
Killer, M; Trinka, E; Kraus, J; Broussalis, E;
Expert Opin Drug Discov. 2011; 6(4): 353-369.
Reviews
Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Rivera, FJ; Kraus, J; Steffenhagen, C; Kury, P; Weidner, N; Aigner, L
CURR SIGNAL TRANSD T. 2011; 6(3): 293-313.
Reviews
The increasing incidence and prevalence of female multiple sclerosis-A critical analysis of potential environmental factors
Sellner, J; Kraus, J; Awad, A; Milo, R; Hemmer, B; Stuve, O
AUTOIMMUN REV. 2011; 10(8): 495-502.
Reviews
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Reviews
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Full papers/articles (Journal)
Acute pulmonary edema caused by a multiple sclerosis relapse.
Wipfler, P; Pilz, G; Broussalis, E; Golaszewski, SM; Kunz, A; Trinka, E; Kraus, J;
J Neurol. 2011; 258(6): 1176-1179.
Letters
Conference papers, proceedings, abstracts
FUNCTIONAL INVOLVEMENT OF CEREBRAL CORTEX IN PATIENTS WITH SLEEP-WAKE DISTURBANCES AFTER TRAUMATIC BRAIN INJURY: A TMS STUDY
Golaszewski, S; Seidl, M; Kunz, A; Wipfler, P; Kraus, J; Nardone, R; Trinka, E; Gerstenbrand, F
EUR J NEUROL. 2011; 18: 57-57.
Abstracts (Journal)
Natalizumab binding to peripheral blood mononuclear cells analysed by flow cytometry can be used for monitoring treatment response in patients with multiple sclerosis
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 13-14.
Abstracts (Journal)
IMMUNE RESPONSE TO MYELIN AND CYTOPLASMIC PROTEINS IN GUILLAIN-BARRE SYNDROME
Hegen, H; Forstenlechner, J; Schanda, K; Loscher, WN; Beer, R; Eggers, C; Grossmann, J; Gruber, F; Hoger, FS; Holzner, F; Kimla, T; Kraus, J; Schautzer, F; Berger, T; Deisenhammer, F; Wanschitz, J
J PERIPHER NERV SYST. 2011; 16: S54-S55.
Abstracts (Journal)
Anti-Inflammatory Effects of Copaxone on the Level of Adhesion Molecule Expression Patterns during Short- and Long-Term Treatment
Kraus, J; Oppermann, K; Harrer, A; Koczi, W; Duerr, EM; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E
NEUROLOGY. 2011; 76(9): A384-A384.
Abstracts (Journal)
Flow Cytometry of Natalizumab Binding to Immune Cells and Its Potential Use for Monitoring Disease Activity and Treatment Response in Patients with Multiple Sclerosis
Kraus, J; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2011; 76(9): A135-A136.
Abstracts (Journal)
Copaxone treatment shows anti-inflammatory effects on the level of adhesion molecule expression on peripheral blood mononuclear cells during short- and long-term therapy
Oppermann, K; Harrer, A; Koczi, W; Duerr, E; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 206-206.
Abstracts (Journal)
2010
Journal Articles
Relationship between thrombin generation and carotid intima-media thickness.
Bernhard, H; Wipfler, P; Leschnik, B; Novak, M; Kraus, J; Pilz, G; Ladurner, G; Muntean, W;
HAMOSTASEOLOGIE. 2010; 30 Suppl 1: S168-S171.
Full papers/articles (Journal)
First detection of the Anaplasma phagocytophilum groEL-A genotype in man.
Haschke-Becher, E; Bernauer, R; Walleczek, AM; Apfalter, P; Afazel-Saeedi, S; Kraus, J; Ladurner, G; Strasser, P;
J INFECTION. 2010; 60(4): 300-305.
Case Reports
Current endovascular treatment of acute stroke and future aspects.
Killer, M; Ladurner, G; Kunz, AB; Kraus, J;
DRUG DISCOV TODAY. 2010; 15(15-16): 640-647.
Reviews
Use of a blood-brain barrier model as a bioassay for the IFN-beta-1b-Response Correlation with clinical and MR data
Muller, M; Frese, A; Nassenstein, I; Hoppen, M; Marziniak, M; Ringelstein, EB; Kim, KS; Schabitz, WR; Kraus, J
NERVENARZT. 2010; 81: 33-34.
Full papers/articles (Journal)
Cholinergic dysfunction and amnesia in patients with Wernicke-Korsakoff syndrome: a transcranial magnetic stimulation study.
Nardone, R; Bergmann, J; De Blasi, P; Kronbichler, M; Kraus, J; Caleri, F; Tezzon, F; Ladurner, G; Golaszewski, S;
J NEURAL TRANSM. 2010; 117(3): 385-391.
Full papers/articles (Journal)
Spontaneous subdural spinal haematoma presenting as occipital headache: a case report.
Nardone, R; Kunz, A; Kraus, J; Staffen, W; Ladurner, G; Trinka, E; Golaszewski, S;
Acta Neurol Belg. 2010; 110(3): 268-269.
Case Reports
Hyponatremic Encephalopathy Mimicking Hypoxic-Ischemic Encephalopathy
Nardone, R; McCoy, M; Kunz, AB; Kraus, J; Staffen, W; Ladurner, G; Golaszewski, SM
CLIN NEURORADIOL. 2010; 20(4): 243-246.
Letters
Invasive aspergillosis presenting with a painless complete ophthalmoplegia
Wipfler, P; Pilz, G; Golaszewski, S; Luthringshausen, G; Berr, F; Kemmerling, R; Neureiter, D; Ladurner, G; Kraus, J
CLIN NEUROL NEUROSUR. 2010; 112(1): 85-87.
Case Reports
Conference papers, proceedings, abstracts
Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections
Kraus, J; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Afazel, S; Haschke-Becher, E; Kunz, AB; Golaszewski, SM; Staffen, W; Ladurner, G
NEUROLOGY. 2010; 74(9): A416-A416.
Abstracts (Journal)
Short- and long-term decrease of soluble adhesion molecules (sICAM-1,-2,-3 and sVCAM-1) during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Harrer, A; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S220-S220.
Abstracts (Journal)
Expression levels of cell surface bound interferon-receptor remain stable during short- and long-term interferon beta-1b treatment
Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Duerr, EM; Koczi, W; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S219-S219.
Abstracts (Journal)
Relationship between markers of endothelial damage and intima-media thickness in asymptomatic subjects
Wipfler, P; Bernhard, H; Leschnik, B; Pilz, G; Kraus, J; Muntean, W
J NEUROL. 2010; 257: S86-S86.
Abstracts (Journal)
Accumulation of natalizumab at the VLA-4 receptor as a potential molecular basis of enhanced treatment efficacy and occurrence of opportunistic infections
Wipfler, P; Oppermann, K; Pilz, G; Harrer, A; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S8-S8.
Abstracts (Journal)
2009
Journal Articles
Obliterating intracranial vasculopathy mimicking multiple sclerosis.
Boentert, M; Kraus, J; Kloska, S; Dittrich, R; Nabavi, DG; Niederstadt, T; Ringelstein, EB; Kiefer, R;
ACTA NEUROL SCAND. 2009; 120(1): 68-71.
Editorials
[Acute polyneuritis and polyradiculoneuritis: uncommon causes and their pathomechanisms].
Duning, T; Kraus, J; Schäbitz, WR;
FORTSCHR NEUROL PSYC. 2009; 77(4): 218-227.
Reviews
[Cognitive dysfunction as a hidden multiple sclerosis related symptom relevant for an expert appraisal].
Kraus, J; Lohmann, H; Evers, S;
FORTSCHR NEUROL PSYC. 2009; 77(1): 38-43.
Case Reports
Blood-Brain-Restrain-Model as Bioassay for the IFN-beta-Response
Kraus, J; Muller, M; Frese, A; Hoppen, M; Kim, KS; Ringelstein, EB; Schabitz, WR
NERVENARZT. 2009; 80: 38-39.
Full papers/articles (Journal)
Goat Cheese and Spondylodiscitis
Pilz, G; Hold, R; Wipfler, P; Iglseder, B; Hell, M; Golaszewski, S; Ladurner, G; Kraus, J
AKTUEL NEUROL. 2009; 36(8): 418-420.
Case Reports
Cranial Venous Outflow Under Lower Body Positive and Negative Pressure Conditions and Head-Up and -Down Tilts
Stolz, E; Fox, BC; Hoffmann, O; Gerriets, T; Blaes, F; Kraus, J; Kaps, M
J NEUROIMAGING. 2009; 19(1): 31-36.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Serum from MS patients treated with interferon beta-1b leads to a stabilisation of the blood-brain barrier in vitro
Muller, M; Frese, A; Nassenstein, I; Hoppen, M; Marziniak, M; Ringelstein, EB; Kim, KS; Schabitz, WR; Kraus, J
MULT SCLER. 2009; 15(9): S240-S240.
Abstracts (Journal)
Short-term decrease of soluble adhesion molecules during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Sulzer, C; Afazel, S; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Journal)
Therapeutic effect of natalizumab despite the presence of neutralising antibodies shown by cell surface bound alpha4-integrin expression
Pilz, G; Wipfler, P; Oppermann, K; Sulzer, C; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Journal)
Endogenous thrombin potential is associated with carotid intima-media thickness in subjects younger than 45 years
Wipfler, P; Bernhard, H; Pilz, G; Kraus, J; Afazel, S; Ladurner, G; Leschnik, B; Novak, M; Muntean, W
J NEUROL. 2009; 256: S51-S51.
Abstracts (Journal)
Natalizumab Treatment Leads to Changes in Adhesion Molecule Expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G; Kraus, J
NEUROLOGY. 2009; 72(11): A37-A38.
Abstracts (Journal)
Long-term effect of natalizumab on cell surface bound adhesion molecules expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Huemer, M; Haschke-Becher, E; Staffen, W; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S195-S196.
Abstracts (Journal)
2008
Journal Articles
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Kraus, J; Voigt, K; Schuller, AM; Scholz, M; Kim, KS; Schilling, M; Schäbitz, WR; Oschmann, P; Engelhardt, B;
MULT SCLER. 2008; 14(6): 843-852.
Full papers/articles (Journal)
Modern multiple sclerosis treatment - what is approved, what is on the horizon.
Pilz, G; Wipfler, P; Ladurner, G; Kraus, J;
Drug Discov Today. 2008; 13(23-24):1013-1025
Reviews
Klebsiella meningoencephalitis presenting like embolic ischemic stroke.
Wipfler, P; Pilz, G; Lesicky, O; Golaszewski, SM; Ladurner, G; Kraus, J;
J NEUROL. 2008; 255(12): 1983-1984.
Letters
Conference papers, proceedings, abstracts
Changes in adhesion molecule expression induced by natalizumab treatment in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G
MULT SCLER. 2008; 14: S133-S133.
Abstracts (Journal)
Influence of natalizumab treatment on a panel of cell surface bound adhesion molecules
Wipfler, P; Pilz, G; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G; Kraus, J
J NEUROL. 2008; 255: 211-211.
Abstracts (Journal)
2007
Journal Articles
Management of autonomic dysfunction in severe tetanus: the importance of deep analgosedation
Duning, T; Kraus, J; Nabavi, DG; Schaebitz, WR
INTENS CARE MED. 2007; 33(2): 380-381.
Case Reports
C-reactive protein and fibrinogen in acute stroke patients with and without sleep apnea.
Dziewas, R; Ritter, M; Kruger, L; Berger, S; Langer, C; Kraus, J; Dittrich, R; Schabitz, WR; Ringelstein, EB; Young, P;
CEREBROVASC DIS. 2007; 24(5): 412-417.
Full papers/articles (Journal)
CRMP-5-autoantibodies in testicular cancer associated with limbic encephalitis and choreiform dyskinesias
Kellinghaus, C; Kraus, J; Blaes, F; Nabavi, DG; Schabitz, WR
EUR NEUROL. 2007; 57(4): 241-243.
Letters
Time course of VCAM-1 and ICAM-1 in CSF in patients with basal ganglia haemorrhage.
Kraus, J; Gerriets, T; Leis, S; Stolz, E; Oschmann, P; Heckmann, JG;
Acta Neurol Scand. 2007; 116(1):49-55
Full papers/articles (Journal)
[Prolonged migrainous aura and acute ischemic insult. Differential diagnosis by diffusion- and perfusion-weighted cMRI].
Kraus, J; Golaszewski, S; Luthringshausen, G; Hold, R; Pilz, G; Tasch, G; Ladurner, G;
NERVENARZT. 2007; 78(12): 1420-1424.
Full papers/articles (Journal)
Temporal coincidence between AMAN type of GBS and myasthenia gravis.
Kraus, J; Teismann, I; Kellinghaus, C; Duning, T; Ringelstein, EB; Nabavi, DG; Schabitz, WR
J Neurol. 2007; 254(2):264-265
Letters
Improvement of advanced postvaccinal demyelinating encephalitis due to plasmapheresis.
Rogalewski, A; Kraus, J; Hasselblatt, M; Kraemer, C; Schäbitz, WR;
Neuropsychiatr Dis Treat. 2007; 3(6):987-991
Full papers/articles (Journal)
Thrombocyte activation increases with the degree of carotid artery stenosis.
Stolz, E; Oschmann, P; Pötzsch, B; Kraus, J; Kaps, M;
J Stroke Cerebrovasc Dis. 2007; 11(6):324-329
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Brain endothelioma cell stimulation with VEGF and H2O2 is independent of P 38
Hartmann, K; Voigt, K; Kraus, J; Clauss, M
J NEUROL. 2007; 254: 193-193.
Abstracts (Journal)
Stimulation of brain endothelial cells with VEGF and menadion is independent of P 38
Hartmann, K; Voigt, K; Kraus, J; Clauss, M
J NEUROL. 2007; 254: 192-193.
Abstracts (Journal)
Perfusion abnormalities in cerebral magnetic resonance imaging in two patients with prolonged mirgrainous aura
Kraus, J; Golaszewski, S; Luthringshausen, G; Hold, R; Pilz, G; Ladurner, G
J NEUROL. 2007; 254: 142-142.
Abstracts (Journal)
Colony stimulating factors stabilize the permeability barrier in a human blood-brain barrier in vitro model - implications for treatment of neurological diseases
Kraus, J; Hoppen, M; Kim, KS; Schilling, M; Oschmann, P; Schabitz, WR
J NEUROL. 2007; 254: 47-47.
Abstracts (Journal)
2006
Journal Articles
Acute toxic polyradiculopathy after exorbitant intracarotid substance abuse.
Kraus, J; Baumeier, A; Boentert, M; Husstedt, IW; Nabavi, DG; Ringelstein, EB; Schäbitz, WR;
J Neurol. 2006; 253(6):815-816
Letters
The impact of interferon-beta treatment on the blood-brain barrier.
Kraus, J; Oschmann, P;
Drug Discov Today. 2006; 11(15-16):755-762
Reviews
Conference papers, proceedings, abstracts
G-CSF stabilises blood-brain barrier characteristics of human brain microvascular endothelial cells in vitro
Kraus, J; Hoppen, M; Kim, KS; Schilling, M; Schmann, P; Schabitz, WR
MULT SCLER. 2006; 12: S53-S53.
Abstracts (Journal)
Circadian rhythmicity of cytokines and cytokine receptors in the serum of multiple sclerosis patients
Kraus, J; Kreiling, A; Mannes-Keil, S; Retzlaff, K; Oschmann, P
MULT SCLER. 2006; 12: S218-S218.
Abstracts (Journal)
2005
Journal Articles
Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and long-term outcome.
Stolz, E; Rahimi, A; Gerriets, T; Kraus, J; Kaps, M;
Clin Neurol Neurosurg. 2005; 107(2):99-107
Full papers/articles (Journal)
2004
Journal Articles
CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis, N; Kraus, J; Bauer, R; Engelhardt, B; Bregenzer, T; Kuehne, BS; Tofighi, J; Laske, C; Stolz, E; Blaes, F; Voigt, K; Traupe, H; Kaps, M; Oschmann, P;
ACTA NEUROL SCAND. 2004; 110(6): 377-385.
Full papers/articles (Journal)
Astrocyte mediated modulation of blood-brain barrier permeability does not correlate with a loss of tight junction proteins from the cellular contacts
Hamm, S; Dehouck, B; Kraus, J; Wolburg-Buchholz, K; Wolburg, H; Risau, W; Cecchelli, R; Engelhardt, B; Dehouck, MP
CELL TISSUE RES. 2004; 315(2): 157-166.
Full papers/articles (Journal)
Interferon-beta(1b) leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis
Kraus, J; Bauer, R; Chatzimanolis, N; Engelhardt, B; Tofighi, J; Bregenzer, T; Kuehne, BS; Stolz, E; Blaes, F; Morgen, K; Traupe, H; Kaps, M; Oschmann, P
J NEUROL. 2004; 251(4): 464-472.
Full papers/articles (Journal)
Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro.
Kraus, J; Ling, AK; Hamm, S; Voigt, K; Oschmann, P; Engelhardt, B;
Ann Neurol. 2004; 56(2):19-205
Full papers/articles (Journal)
2003
Journal Articles
Adult paraneoplastic opsoclonus-myoclonus syndrome associated with antimitochondrial autoantibodies.
Blaes, F; Jauss, M; Kraus, J; Oschmann, P; Krasenbrink, I; Kaps, M; Teegen, B;
J Neurol Neurosurg Psychiatry. 2003; 74(11):1595-1596
Letters
Increased monocyte tissue factor activity in women following cerebral venous thrombosis.
Hölschermann, H; Haberbosch, W; Terhalle, HM; Parviz, B; Kraus, J; Kemkes-Matthes, B; Tillmanns, H; Kaps, M; Stolz, E;
J Neurol. 2003; 250(5):631-632
Letters
Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme.
Wolburg, H; Wolburg-Buchholz, K; Kraus, J; Rascher-Eggstein, G; Liebner, S; Hamm, S; Duffner, F; Grote, EH; Risau, W; Engelhardt, B;
Acta Neuropathol. 2003; 105(6):586-592
Full papers/articles (Journal)
2002
Journal Articles
Disturbance in the serum IgG subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes.
Blaes, F; Klotz, M; Funke, D; Strittmatter, M; Kraus, J; Kaps, M;
Eur J Neurol. 2002; 9(4): 369-372.
Full papers/articles (Journal)
Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity.
Kraus, J; Engelhardt, B; Chatzimanolis, N; Bauer, R; Tofighi, J; Kuehne, BS; Laske, C; Stolz, E; Frielinghaus, P; Schaefer, C; Blaes, F; Traupe, H; Kaps, M; Oschmann, P;
J Neuroimmunol. 2002; 122(1-2): 17-85.
Full papers/articles (Journal)
Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis.
Kraus, J; Kuehne, BS; Tofighi, J; Frielinghaus, P; Stolz, E; Blaes, F; Laske, C; Engelhardt, B; Traupe, H; Kaps, M; Oschmann, P;
Acta Neurol Scand. 2002; 105(4): 300-308.
Full papers/articles (Journal)
High concentrations of sVCAM-1 and sICAM-1 in the cerebrospinal fluid of patients with intracerebral haemorrhage are associated with poor outcome.
Kraus, J; Oschmann, P; Leis, S; Neundörfer, B; Heckmann, JG;
J Neurol Neurosurg Psychiatry. 2002; 73(3): 346-347.
Letters
Intracranial venous hemodynamics in patients with midline dislocation due to postischemic brain edema.
Stolz, E; Gerriets, T; Babacan, SS; Jauss, M; Kraus, J; Kaps, M;
Stroke. 2002; 33(2): 479-485.
Full papers/articles (Journal)
2001
Journal Articles
Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity.
Laske, C; Oschmann, P; Tofighi, J; Kuehne, SB; Diehl, H; Bregenzer, T; Kraus, J; Bauer, R; Chatzimanolis, N; Kern, A; Traupe, H; Kaps, M;
Acta Neurol Scand. 2001; 103(2): 105-113.
Full papers/articles (Journal)
2000
Journal Articles
Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity.
Kraus, J; Oschmann, P; Engelhardt, B; Bauer, R; Schiel, C; Kern, A; Stolz, E; Traupe, A; Dorndorf, W;
Acta Neurol Scand. 2000; 101(2): 135-139.
Full papers/articles (Journal)
CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis.
Kraus, J; Oschmann, P; Engelhardt, B; Stolz, E; Kuehne, BS; Laske, C; Schaefer, C; Traupe, H; Kaps, M;
Acta Neurol Scand. 2000; 102(5): 326-332.
Full papers/articles (Journal)
[Generalized brain edema in non-purulent meningoencephalitis. The anti-edema effect of therapy with dexamethasone].
Sommer, JB; Heckmann, JG; Kraus, J; Neundörfer, B; Erbguth, FJ;
Nervenarzt. 2000; 71(2): 112-115.
Case Reports
Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis.
Stolz, E; Kemkes-Matthes, B; Pötzsch, B; Hahn, M; Kraus, J; Wirbartz, A; Kaps, M;
Acta Neurol Scand. 2000; 102(1): 31-36.
Full papers/articles (Journal)
1999
Journal Articles
[Nosocomial pneumonias in a neurology intensive care unit].
Heckmann, JG; Kraus, J; Niedermeier, W; Erbguth, F; Druschky, A; Schoerner, C; Neundörfer, B;
Dtsch Med Wochenschr. 1999; 124(31-32): 919-924.
Full papers/articles (Journal)
Ondine's curse in association with diabetes insipidus following transient vertebrobasilar ischemia.
Kraus, J; Heckmann, JG; Druschky, A; Erbguth, F; Neundorfer, B;
Clin Neurol Neurosurg. 1999; 101(3): 196-198.
Case Reports
1998
Journal Articles
Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis.
Kraus, J; Oschmann, P; Engelhardt, B; Schiel, C; Hornig, C; Bauer, R; Kern, A; Traupe, H; Dorndorf, W;
Acta Neurol Scand. 1998; 98(2): 102-109.
Full papers/articles (Journal)